– Reported positive top-line data from Phase 2a proof-of-concept (POC) trial of EVO301 in atopic dermatitis (AD) – EVO756 on track to report Phase 2b top-line data...
Evommune, Inc. (“Evommune” or the “Company”) (NYSE: EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today...
- Trial met primary efficacy endpoint at week 12 - EVO301 produced rapid, statistically significant EASI reductions at weeks 4, 8 and 12 versus placebo ...
2026 could be a pivotal year for three biotech names, including a standout in the hemodialysis space and two emerging companies with strong pipelines.
- Three Phase 2 data readouts from lead programs, EVO756 and EVO301, expected in 2026 across atopic dermatitis (AD) and chronic spontaneous urticaria (CSU) - Well capitalized...
PALO ALTO, Calif. , Nov. 5, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory...
PALO ALTO, Calif. , Oct. 30, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory...